Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Janux Therapeutics, Inc. (JANX)

12.1   0.5 (4.31%) 03-31 16:00
Open: 11.65 Pre. Close: 11.6
High: 12.42 Low: 11.65
Volume: 89,102 Market Cap: 565(M)

Technical analysis

as of: 2023-03-31 4:19:52 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 17.39     One year: 20.29
Support: Support1: 10.86    Support2: 9.04
Resistance: Resistance1: 14.89    Resistance2: 17.37
Pivot: 12.21
Moving Average: MA(5): 11.81     MA(20): 12.95
MA(100): 15.66     MA(250): 14.07
MACD: MACD(12,26): -1.4     Signal(9): -1.5
Stochastic oscillator: %K(14,3): 29     %D(3): 22.2
RSI: RSI(14): 39.5
52-week: High: 23.63  Low: 9.39
Average Vol(K): 3-Month: 124 (K)  10-Days: 115 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ JANX ] has closed above bottom band by 47.1%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 13.19 - 13.26 13.26 - 13.31
Low: 11.08 - 11.14 11.14 - 11.19
Close: 11.51 - 11.61 11.61 - 11.69

Company Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Headline News

Wed, 15 Mar 2023
7 Biotech Stocks That Could Be the Next Big Thing - Nasdaq

Wed, 15 Mar 2023
HC Wainwright Comments on Janux Therapeutics, Inc.'s Q1 2023 ... - MarketBeat

Fri, 10 Mar 2023
Janux Therapeutics Q4 EPS Beats Analyst Estimates and Reports ... - Best Stocks

Fri, 10 Mar 2023
Housing, Manufacturing Stats Due Next Week -

Fri, 10 Mar 2023
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 ... - Business Wire

Tue, 14 Feb 2023
Janux Therapeutics to Participate in Novel IO Panel Discussion at ... - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 42 (M)
Shares Float 11 (M)
% Held by Insiders 11 (%)
% Held by Institutions 103.5 (%)
Shares Short 2,150 (K)
Shares Short P.Month 2,390 (K)

Stock Financials

EPS -1.56
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.05
Profit Margin (%) 0
Operating Margin (%) -844.1
Return on Assets (ttm) -10.2
Return on Equity (ttm) -17.1
Qtrly Rev. Growth 56.4
Gross Profit (p.s.) -0.55
Sales Per Share 0.17
EBITDA (p.s.) -1.49
Qtrly Earnings Growth 0
Operating Cash Flow -41 (M)
Levered Free Cash Flow -27 (M)

Stock Valuations

PE Ratio -7.76
PEG Ratio -1.3
Price to Book value 1.33
Price to Sales 68.3
Price to Cash Flow -12.15

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.